Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 2
2018 1
2019 2
2020 1
2021 5
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Targeted α-Therapy Using 225Ac Radiolabeled Single-Domain Antibodies Induces Antigen-Specific Immune Responses and Instills Immunomodulation Both Systemically and at the Tumor Microenvironment.
Ertveldt T, Krasniqi A, Ceuppens H, Puttemans J, Dekempeneer Y, Jonghe K, Mey W, Lecocq Q, Vlaeminck Y, Awad RM, Goyvaerts C, Veirman K, Morgenstern A, Bruchertseifer F, Keyaerts M, Devoogdt N, D'Huyvetter M, Breckpot K. Ertveldt T, et al. Among authors: puttemans j. J Nucl Med. 2023 May;64(5):751-758. doi: 10.2967/jnumed.122.264752. Epub 2023 Apr 13. J Nucl Med. 2023. PMID: 37055223
The Road to Personalized Myeloma Medicine: Patient-specific Single-domain Antibodies for Anti-idiotypic Radionuclide Therapy.
Puttemans J, Stijlemans B, Keyaerts M, Vander Meeren S, Renmans W, Fostier K, Debie P, Hanssens H, Rodak M, Pruszynski M, De Veirman K, Vanderkerken K, Lahoutte T, Morgenstern A, Bruchertseifer F, Devoogdt N, D'Huyvetter M. Puttemans J, et al. Mol Cancer Ther. 2022 Jan;21(1):159-169. doi: 10.1158/1535-7163.MCT-21-0220. Epub 2021 Oct 19. Mol Cancer Ther. 2022. PMID: 34667109 Free PMC article.
Imaging of Glioblastoma Tumor-Associated Myeloid Cells Using Nanobodies Targeting Signal Regulatory Protein Alpha.
De Vlaminck K, Romão E, Puttemans J, Pombo Antunes AR, Kancheva D, Scheyltjens I, Van Ginderachter JA, Muyldermans S, Devoogdt N, Movahedi K, Raes G. De Vlaminck K, et al. Among authors: puttemans j. Front Immunol. 2021 Nov 30;12:777524. doi: 10.3389/fimmu.2021.777524. eCollection 2021. Front Immunol. 2021. PMID: 34917090 Free PMC article.
Preclinical Targeted α- and β--Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies.
Puttemans J, Dekempeneer Y, Eersels JL, Hanssens H, Debie P, Keyaerts M, Windhorst AD, van der Aa F, Lecocq Q, Breckpot K, Morgenstern A, Bruchertseifer F, Lahoutte T, Devoogdt N, D'Huyvetter M. Puttemans J, et al. Cancers (Basel). 2020 Apr 21;12(4):1017. doi: 10.3390/cancers12041017. Cancers (Basel). 2020. PMID: 32326199 Free PMC article.
CS1-specific single-domain antibodies labeled with Actinium-225 prolong survival and increase CD8+ T cells and PD-L1 expression in Multiple Myeloma.
De Veirman K, Puttemans J, Krasniqi A, Ertveldt T, Hanssens H, Romao E, Hose D, Goyvaert C, Vlummens P, Muyldermans S, Breckpot K, Bruchertseifer F, Morgenstern A, D'Huyvetter M, Devoogdt N. De Veirman K, et al. Among authors: puttemans j. Oncoimmunology. 2021 Nov 9;10(1):2000699. doi: 10.1080/2162402X.2021.2000699. eCollection 2021. Oncoimmunology. 2021. PMID: 34777918 Free PMC article.
Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior.
Dekempeneer Y, Bäck T, Aneheim E, Jensen H, Puttemans J, Xavier C, Keyaerts M, Palm S, Albertsson P, Lahoutte T, Caveliers V, Lindegren S, D'Huyvetter M. Dekempeneer Y, et al. Among authors: puttemans j. Mol Pharm. 2019 Aug 5;16(8):3524-3533. doi: 10.1021/acs.molpharmaceut.9b00354. Epub 2019 Jul 3. Mol Pharm. 2019. PMID: 31268724 Free article.
12 results